Short Interest in Cesca Therapeutics Inc (NASDAQ:KOOL) Grows By 14.1%

Cesca Therapeutics Inc (NASDAQ:KOOL) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 208,500 shares, an increase of 14.1% from the September 15th total of 182,700 shares. Currently, 12.1% of the shares of the stock are sold short. Based on an average daily volume of 202,800 shares, the days-to-cover ratio is currently 1.0 days.

Shares of KOOL stock opened at $5.14 on Friday. Cesca Therapeutics has a 1 year low of $2.10 and a 1 year high of $7.00. The stock has a market cap of $10.68 million, a PE ratio of -1.43 and a beta of 1.07. The business’s fifty day moving average is $5.55 and its 200-day moving average is $2.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.91 and a current ratio of 1.52.

Cesca Therapeutics (NASDAQ:KOOL) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative return on equity of 77.30% and a negative net margin of 98.84%. The company had revenue of $4.31 million for the quarter, compared to analysts’ expectations of $3.40 million. Equities research analysts predict that Cesca Therapeutics will post -0.26 earnings per share for the current year.

KOOL has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.50 price target (up from $6.50) on shares of Cesca Therapeutics in a research report on Thursday, October 3rd. Zacks Investment Research upgraded Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Tuesday, August 20th. Finally, ValuEngine upgraded Cesca Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Recommended Story: Stop Order

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with's FREE daily email newsletter.